FTH
Faeth Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$40.05
+2.69%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.66
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$2.84
- EPS estimate
- -$2.64
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -7.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $56
- PT range
- $51 – $60
- Analysts
- 8
8 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026